Post-earnings recap
Reported
Mon, Nov 14, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axovant Gene Therapies reported a loss per share of $0.38, but the stock still rose by 2.74%. Investors may be reacting positively to management's focus on their pipeline and future clinical trials, despite the lack of revenue figures and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism about their ongoing projects. They emphasized the significance of their clinical trials for future growth.
Management highlighted ongoing development efforts and commitment to advancing their pipeline.
They noted the importance of upcoming clinical trials in shaping future prospects.